Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2020 3
2021 1
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Reducing affinity as a strategy to boost immunomodulatory antibody agonism.
Yu X, Orr CM, Chan HTC, James S, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, Cox KL, Essex JW, Tews I, Glennie MJ, Cragg MS. Yu X, et al. Among authors: inzhelevskaya t. Nature. 2023 Feb;614(7948):539-547. doi: 10.1038/s41586-022-05673-2. Epub 2023 Feb 1. Nature. 2023. PMID: 36725933
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Simpson AP, Roghanian A, Oldham RJ, Chan HTC, Penfold CA, Kim HJ, Inzhelevskaya T, Mockridge CI, Cox KL, Bogdanov YD, James S, Tutt AL, Rycroft D, Morley P, Dahal LN, Teige I, Frendeus B, Beers SA, Cragg MS. Simpson AP, et al. Among authors: inzhelevskaya t. Cell Rep. 2022 Jul 19;40(3):111099. doi: 10.1016/j.celrep.2022.111099. Cell Rep. 2022. PMID: 35858562 Free PMC article.
Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
Moreno-Vicente J, Willoughby JE, Taylor MC, Booth SG, English VL, Williams EL, Penfold CA, Mockridge CI, Inzhelevskaya T, Kim J, Chan HTC, Cragg MS, Gray JC, Beers SA. Moreno-Vicente J, et al. Among authors: inzhelevskaya t. J Immunother Cancer. 2022 Jan;10(1):e003735. doi: 10.1136/jitc-2021-003735. J Immunother Cancer. 2022. PMID: 35017153 Free PMC article.
Immune characterization of pre-clinical murine models of neuroblastoma.
Webb ER, Lanati S, Wareham C, Easton A, Dunn SN, Inzhelevskaya T, Sadler FM, James S, Ashton-Key M, Cragg MS, Beers SA, Gray JC. Webb ER, et al. Among authors: inzhelevskaya t. Sci Rep. 2020 Oct 7;10(1):16695. doi: 10.1038/s41598-020-73695-9. Sci Rep. 2020. PMID: 33028899 Free PMC article.
Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility.
Orr CM, Fisher H, Yu X, Chan CH, Gao Y, Duriez PJ, Booth SG, Elliott I, Inzhelevskaya T, Mockridge I, Penfold CA, Wagner A, Glennie MJ, White AL, Essex JW, Pearson AR, Cragg MS, Tews I. Orr CM, et al. Among authors: inzhelevskaya t. Sci Immunol. 2022 Jul 15;7(73):eabm3723. doi: 10.1126/sciimmunol.abm3723. Epub 2022 Jul 8. Sci Immunol. 2022. PMID: 35857577
Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
Griffiths J, Hussain K, Smith HL, Sanders T, Cox KL, Semmrich M, Mårtensson L, Kim J, Inzhelevskaya T, Penfold CA, Tutt AL, Mockridge CI, Chan HC, English V, French RF, Teige I, Al-Shamkhani A, Glennie MJ, Frendeus BL, Willoughby JE, Cragg MS. Griffiths J, et al. Among authors: inzhelevskaya t. J Immunother Cancer. 2020 Dec;8(2):e001557. doi: 10.1136/jitc-2020-001557. J Immunother Cancer. 2020. PMID: 33428585 Free PMC article.
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Yu X, Chan HTC, Fisher H, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, French RR, Duriez PJ, Douglas LR, English V, Verbeek JS, White AL, Tews I, Glennie MJ, Cragg MS. Yu X, et al. Among authors: inzhelevskaya t. Cancer Cell. 2020 Jun 8;37(6):850-866.e7. doi: 10.1016/j.ccell.2020.04.013. Epub 2020 May 21. Cancer Cell. 2020. PMID: 32442402 Free PMC article.